Umeclidinium/fluticasone furoate

Drug Profile

Umeclidinium/fluticasone furoate

Alternative Names: Fluticasone furoate/umeclidinium; GSK 685698/GSK 573719

Latest Information Update: 02 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Androstadienes; Antiallergics; Antiasthmatics; Benzhydryl compounds; Bronchodilators; Glucocorticoids; Quinuclidines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Asthma

Most Recent Events

  • 02 Mar 2016 Umeclidinium/fluticasone furoate is in phase II development for Asthma COPD overlap syndrome
  • 01 Apr 2012 Phase-II clinical trials in Asthma in USA, Argentina, Chile, Thailand and Russia (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top